Understanding
Mozobil®
(plerixafor injection)
International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hol ywood, CA 91607 USA
Telephone:
800-452-CURE (2873)
(USA & Canada)
818-487-7455
Fax: 818-487-7454
TheIMF@myeloma.org
myeloma.org
Improving lives · Finding the cure

---

Table of Contents
Introduction
5
What is Multiple Myeloma?
6
What is Mozobil®?
7
How does Mozobil® work?
8
What are the possible side effects
of Mozobil®?
8
How is Mozobil® given?
11
What treatments may be given instead of,
or in addition to, Mozobil®?
11
Questions & Answers about
Stem Cell Mobilization
13
Questions for the Doctor
17
About the IMF
21
Glossary
24
Bibliography
27
©2011, International Myeloma Foundation, North Hol ywood, California (11-K)

---

Introduction
This booklet explains important details about
the drug Mozobil® (plerixafor injection).
Mozobil® is used to mobilize hematopoietic
(blood cel -making) stem cel s in patients
who are candidates for autologous stem
cel transplants (SCT). Another booklet in
the International Myeloma Foundation's
Understanding series, Understanding Stem
Cel Transplant, explains the stem cel trans-
plantation process in detail. "Questions and
Answers" about stem cel mobilization as
wel as "Questions to Ask the Doctor" about
the procedure are included in this booklet.
After reading this booklet you should know:
n What is Mozobil®?
n How does Mozobil® work?
n What are the possible side ef ects of
Mozobil®?
n How is Mozobil® given?
n What treatments may be given instead of
or in addition to Mozobil®?
The booklet is meant to provide you with
general information only. It is not meant to
replace the advice of your doctor, nurse, or
other healthcare practitioners. Your health-
care team can answer specific questions
related to your personal treatment plan. Al
words that appear in bold type are defined
in the glossary at the back of this booklet.
4
5

---

Multiple myeloma is a serious cancer, but it
What is Multiple Myeloma?
is very treatable. Many patients experience
Multiple myeloma (also known as myeloma
a series of responses, relapses, and remis-
and plasma cel myeloma) is a cancer of
sions. New treatments may extend the aver-
the immunoglobulin-producing plasma cel s
age survival of 5 years or more for patients
found in the bone marrow. It is a cancer
diagnosed with multiple myeloma. Patients
that involves the immune system. The cancer-
with myeloma can live over 10 years; some
ous plasma cel s, or myeloma cel s, rarely
live over 20 years.
enter the blood stream. The myeloma cel s
accumulate in the bone marrow, causing the
What is Mozobil®?
fol owing:
Mozobil® is used to mobilize stem cel s in
n Disruption of normal bone marrow func-
patients with multiple myeloma (or non-
tion, most commonly causing anemia (a
Hodgkin's lymphoma) who are candidates
low level of red blood cel s in the blood-
for autologous stem cel transplants. It is
stream), although reduction in white blood
used in combination with granulocyte-colony
cel and platelet counts can also occur
stimulating factor (G-CSF) to mobilize (move)
n Damage to bone surrounding accumulated
hematopoietic stem cel s from the bone mar-
myeloma cel s
row to the circulating (peripheral) blood
so that they can be col ected and used to
n Release of an abnormal protein, mono-
support autologous stem cel transplanta-
clonal protein (M protein), into the blood
tion in patients with multiple myeloma.
stream and/or urine
(See figure 1) In an autologous stem cel
n Suppression of normal immune function,
transplant, stem cel s are col ected from a
observed as reduced levels of normal
patient with myeloma fol owing initial ther-
immunoglobulins and increased suscepti-
apy and given back after high-dose melpha-
bility to infection.
lan therapy has been administered to rescue
the patient by enabling him or her to pro-
Myeloma cel s can also grow in the form
duce mature and healthy blood cel s. This is
of localized tumors or plasmacytomas.
Plasmacytomas may be single or multiple,
Red blood cells
carry oxygen to the body's tissues
and either medul ary (confined within bone
Bone
and carbon dioxide away from the tissues
marrow
marrow and bone) or extramedul ary (out-
White blood cells
side of the bone). When there are multiple
fight bacteria, viruses, and fungi that
can cause infection
plasmacytomas inside or outside bone, this
St
S em
tem
cell
cell
condition is also cal ed multiple myeloma.
Platelets
aid in the blood clotting process
Figure 1
6
7

---

the most common type of stem cel transplant.
harvesting process. Leukocytosis, thrombo-
The procedure can be performed once
cytopenia, spleen enlargement, and possible
(single autotransplant) or twice (double or
release of myeloma cel s from the bone mar-
tandem transplant).
row into the circulating blood can occur with
al mobilization techniques.
How does Mozobil® work?
n Leukocytosis is an abnormal increase in
the number of leukocytes or white blood
Normal y, stem cel s are at ached to the
cel s. This can occur because Mozobil®
bone marrow by a protein on their surface.
causes the release of al types of white
Mozobil® binds to this protein and causes
blood cel s, not just stem cel s, into the
the stem cel s to detach from the bone
bloodstream. Your healthcare provider
marrow. The stem cel s are then released
wil monitor your white blood cel counts
into the bloodstream, where they can be
during mobilization.
col ected easily. (See figure 2)
n Thrombocytopenia, or a decreased num-
ber of platelets (thrombocytes), can cause
Blood vessel
a risk of bleeding. Your healthcare pro-
vider wil monitor your platelet counts dur-
ing mobilization.
Bone marrow
n An increase in the size of the spleen
(splenomegaly) was seen in animals given
Stem cell
a dose of Mozobil® much higher than
Figure 2
that given to human patients. Because an
enlarged spleen may be associated with
What are the possible side effects
a risk of rupture (bursting), you should
of Mozobil®?
tel your health care provider if you have
Mozobil® can cause side ef ects. Some side
pain in the upper left abdomen (stomach
ef ects are common but tolerable, and some
area) or in your shoulder or shoulder
side ef ects may be serious. You should let
blade area.
your healthcare provider know if you experi-
n Mozobil® can release myeloma cel s from
ence any of the possible side ef ects after
the bone marrow into the bloodstream.
receiving Mozobil®.
This can result in myeloma cel s being col-
SeriouS Side effectS
lected along with the stem cel s. The ef ect
Please note that the side ef ects are not spe-
of giving patients back their myeloma cel s
cific to Mozobil®, but occur as part of the
is not known.
8
9

---

n The ef ects of giving Mozobil® during preg-
How is Mozobil® given?
nancy are not known. However, Mozobil®
causes birth defects in pregnant animals.
Mozobil® is administered by subcutaneous
(under the skin) injection approximately 11
Therefore, pregnant women should not
hours prior to each apheresis for a total
use Mozobil®, and women are advised to
of up to 4 days. Apheresis involves taking
avoid pregnancy while being treated with
blood from a patient and filtering it through
Mozobil®. If you become pregnant during
a machine. The white blood cel s, which
treatment, you should discuss this with
include the rare stem cel s, are separated
your healthcare provider.
out and stored for transplantation, and the
Potential Side effectS
rest of the blood is returned to the patient.
The most common side ef ects of Mozobil®
G-CSF is also administered each morning for
include diarrhea, nausea, vomiting, fatigue,
4 days prior to the start of Mozobil® admin-
redness and swel ing at the injection site,
istration, and on each morning of apheresis.
joint pain, headaches, and dizziness.
Administration is usual y at the transplant
center or hospital.
Less common side ef ects that have been
reported include abdominal pain and swel -
What treatments may be given
ing, excessive sweating, dry mouth, redness
of the skin, stomach discomfort, constipation,
instead of, or in addition to,
indigestion, muscle or bone pain, a reduced
Mozobil®?
sensation to stimuli such as touch, and a
1. Mozobil® plus growth factors.
general feeling of being unwel .
As you have learned, Mozobil® is used in
Let your healthcare provider know immedi-
combination with blood growth factors to
ately if you are lightheaded or have dif iculty
release stem cel s into the blood so they
breathing after each Mozobil® injection,
can be col ected and used for transplant in
have swel ing around the eyes or itchy skin,
patients with myeloma (as wel as patients
or have any reaction around the site of injec-
tion, because these symptoms can mean you
are having an al ergic reaction to Mozobil®.
Mozobil® can cause orthostatic hypotension,
a sudden drop in blood pressure when stand-
ing up from a sit ing or lying position. This
usual y occurs within one hour of injection
and can be prevented by not standing up
quickly on the days when Mozobil® is given.
10
11

---

with non-Hodgkin's lymphoma). Patients are
therefore longer and much more intensive
treated with growth factors for 4 days prior
than using growth factors with or without
to receiving Mozobil®. Mozobil® is injected
Mozobil. The patient or someone who agrees
subcutaneously 11 hours before the planned
to be responsible may be taught how to give
stem cel col ection for up to 4 consecu-
the growth factor injection so that it can be
tive days. Mozobil® increases the number
administered at home. Some patients may
of stem cel s that can be col ected in few
receive their injections at the transplant cen-
apheresis days.
ter or hospital or from visiting nurses. Once
2. Growth factors alone.
the number of stem cel s in the bloodstream is
White cel growth factors (Neupogen,
high enough, the cel s wil be col ected over
Neulasta, Leukine) used in high doses stimu-
2 to 5 days, while the patient is stil receiving
late the release of stem cel s from the bone
the growth factor injections. Chemotherapy
marrow into the bloodstream. These medica-
drugs usual y used for this purpose include
tions are often used for patients receiving
Cytoxan (cyclophosphamide), VP-16 (eto-
chemotherapy to shorten the time of white
poside), or VDT-PACE (Velcade, dexametha-
blood cel count recovery. They may also be
sone, thalidomide, CisPlatin, Adriamycin,
used alone (without Mozobil®) to mobilize
cyclophoshamide, and etoposide).
stem cel s for col ection. The growth factor
injections are given daily for three or more
Questions & Answers about
days. Stem cel s are usual y col ected on the
Stem Cell Mobilization
4th or 5th day after starting the injections.
Listed below are some of the questions
The col ections and injections wil continue
frequently asked by people with myeloma
daily until sufficient stem cel s are obtained.
who have had, or are considering, stem cel
3. chemotherapy plus growth factors.
mobilization as part of their stem cel trans-
Chemotherapy with growth factors (chemo-
plantation procedure. These questions and
mobilization) may also be used to release
other concerns should be discussed with the
stem cel s from the bone marrow into the
doctor and members of the healthcare team
bloodstream. Your healthcare provider wil
before making any final decisions about the
explain why using chemotherapy in addition
patient's treatment plan.
to growth factors may or may not be right for
Q. Am I a candidate for stem cel mobiliza-
you, and what the potential benefits and side
tion with Mozobil®?
ef ects are. Fol owing chemotherapy for stem
cel mobilization, a white cel growth factor
A. Patients who have either multiple
is given by injection under the skin daily for
myeloma or non-Hodgkin's lymphoma, and
approximately ten days. This procedure is
who are candidates for autologous stem cel
12
13

---

transplant, may be candidates for stem cel
Q. Are there any reasons why Mozobil®
mobilization with Mozobil® given in combi-
should not be used for my mobilization?
nation with G-CSF.
A. Mozobil® is not given to women who are
Q. What are the risk factors for poor stem
pregnant, who are trying to become preg-
cel mobilization?
nant, or who are nursing a baby. Mozobil®
is approved only for patients who are at least
A. Older patients (age 60 years and older)
18 years old. Mozobil® cannot be given to
are at risk for poor stem cel mobilization.
patients who have leukemia.
Patients who have had a prior mobilization
with G-CSF or G-CSF plus chemotherapy may
Q. How does the use of Mozobil® with G-CSF
have a poor repeat stem cel mobilization.
compare with the use of G-CSF alone?
Patients who have had multiple myeloma for
A. The use of Mozobil® is associated with
a long time, or who have received a lot of
a greater chance of col ecting enough stem
radiation therapy to their bone marrow, are
cel s for transplant than using G-CSF alone
also at risk for poor mobilization.
for mobilization, and requires fewer apher-
Q. Does taking alkylating agents such as
esis procedures.
melphalan, busulfan, and cyclophosphamide
Q. What side effects should I anticipate from
(Cytoxan) reduce the likelihood of success-
the mobilization?
ful y mobilizing stem cel s?
A. The most common side ef ects reported
A. The use of melphalan or other alkylating
by patients who received Mozobil® for
agents has been associated with poor stem
mobilization and apheresis include diarrhea,
cel col ection using G-CSF alone.
nausea, fatigue, reactions at the site of injec-
Q. Does the use of Revlimid® affect the abil-
tion, headache, joint pains, dizziness, and
ity to col ect stem cel s?
vomiting. Other more serious side ef ects
A. Patients who have received Revlimid®
(lenalidomide) as initial therapy may mobi-
lize fewer stem cel s with G-CSF and require
more apheresis procedures to col ect enough
stem cel s for a transplant than patients who
have received other types of initial chemo-
therapy for their multiple myeloma.
14
15

---

include increased white blood cel counts,
interact with each other and with prescribed
decreased platelet counts, enlarged spleen,
treatments, and may cause unexpected side
orthostatic hypotension, and the potential for
ef ects. Healthcare providers should be told
birth defects, if given during pregnancy.
the names of al the alternative and com-
plementary therapies being taken so that
Q. Can patients with renal impairment
adjustments to therapies can be made if
(reduced kidney function) receive Mozobil®?
necessary, and dangerous combinations can
A. Patients who have reduced kidney func-
be avoided.
tion may be treated with a lower dose of
Mozobil®.
Questions for the Doctor
Q. How many stem cel s are needed for
These are questions we suggest be discussed
transplantation?
with the doctor to provide bet er understand-
A. In general, at least 2 mil ion stem cel s
ing of the mobilization procedure and its
for every kilogram (2.2 pounds) of body
ef ects on the patient's life. Space is provided
weight must be col ected before a stem cel
for notes:
transplant can be performed. Most centers
"Am I a candidate for stem cel mobilization?"
try to col ect enough stem cel s for at least
two transplants. Those not used are kept
. . . . . . . . . . . . . . . . . . . . .
frozen and stored should they be needed in
. . . . . . . . . . . . . . . . . . . . .
the future.
"What mobilization protocols are there at
Q. How are stem cel s stored prior to
your institution, and how do you decide
transplant?
which one is right for me?"
A. After each apheresis procedure, stem cel s
. . . . . . . . . . . . . . . . . . . . .
are frozen and stored in a special freezer
until they are needed for the transplant.
. . . . . . . . . . . . . . . . . . . . .
Q. What alternative and complementary
. . . . . . . . . . . . . . . . . . . . .
therapies can be taken before and during
"Does taking alkylating agents such as mel-
mobilization?
phalan, busulfan, and Cytoxan, or the use
A. Some patients believe that alternative and
of other agents such as Revlimid, af ect stem
complementary therapies are an important
cel mobilization?"
part of their treatment program. Al drugs,
. . . . . . . . . . . . . . . . . . . . .
whether synthetic or natural, including over-
. . . . . . . . . . . . . . . . . . . . .
the-counter drugs and supplements, may
16
17

---

"What drugs wil be prescribed for use
"How should I prepare for the stem cel
before, during, and after the mobilization?
mobilization?"
What do they do and what are their side
. . . . . . . . . . . . . . . . . . . . .
ef ects?"
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
"What should I do during the mobilization
. . . . . . . . . . . . . . . . . . . . .
procedure?"
"How long is the entire mobilization cycle,
. . . . . . . . . . . . . . . . . . . . .
including preparation through col ection of a
suf icient number of cel s?"
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
"What side ef ects of mobilization should I
anticipate?"
"Is the mobilization procedure done in the
hospital or on an outpatient basis? If in
. . . . . . . . . . . . . . . . . . . . .
hospital, how long wil I have to be in the
. . . . . . . . . . . . . . . . . . . . .
hospital?"
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
"What are the risks of the mobilization
. . . . . . . . . . . . . . . . . . . . .
procedure?"
"How wil the mobilization procedure af ect
. . . . . . . . . . . . . . . . . . . . .
my ability to function? How can I expect to
feel during and after the mobilization?"
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
"Wil stem cel s be col ected for just one or
for two transplants?"
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
18
19

---

"If enough stem cel s for a second transplant
About the IMF
are col ected, where and for how long wil
these cel s be stored for future use?"
"One person can make a dif erence,
Two can make a miracle."
. . . . . . . . . . . . . . . . . . . . .
Brian D. Novis
. . . . . . . . . . . . . . . . . . . . .
IMF Founder
. . . . . . . . . . . . . . . . . . . . .
Myeloma is a lit le-known, complex, and
often misdiagnosed bone marrow cancer
"What is the success rate for mobilization
that at acks and destroys bone. Myeloma
and stem cel col ection at your institu-
af ects approximately 75,000 to 100,000
tion? How does this compare with national
people in the United States, with more than
averages?"
20,000 new cases diagnosed each year.
. . . . . . . . . . . . . . . . . . . . .
Although there is presently no known cure for
myeloma, doctors have many approaches to
. . . . . . . . . . . . . . . . . . . . .
help myeloma patients live bet er and longer.
. . . . . . . . . . . . . . . . . . . . .
The International Myeloma Foundation (IMF)
. . . . . . . . . . . . . . . . . . . . .
was founded in 1990 by Brian and Susie
Novis shortly after Brian's myeloma diagno-
"If you are unable to col ect suf icient stem
sis at the age of 33. It was Brian's dream
cel s for a transplant, what alternative thera-
that future patients would have easy access
pies wil be considered?"
to medical information and emotional sup-
. . . . . . . . . . . . . . . . . . . . .
port throughout their bat le with myeloma.
He established the IMF with the three goals
. . . . . . . . . . . . . . . . . . . . .
of treatment, education, and research. He
. . . . . . . . . . . . . . . . . . . . .
sought to provide a broad spectrum of ser-
vices for patients and, their families, friends,
. . . . . . . . . . . . . . . . . . . . .
and healthcare providers. Although Brian
died four years after his initial diagnosis, his
dream did not. Today, the IMF reaches out
to an international membership of more than
195,000. The IMF was the first organization
dedicated solely to myeloma, and today it
remains the largest.
The IMF provides programs and services to
aid in the research, diagnosis, treatment,
and management of myeloma. The IMF
20
21

---

ensures that no one must brave the myeloma
MyeloMa ManaGerTM PerSonal care aSSiStantTM
bat le alone.
This software program was developed by
We care for patients today, while working
the IMF and is designed specifical y to help
toward tomorrow's cure.
patients and caregivers to capture, display,
and store laboratory test results, and to access
How Can the IMF Help You?
important information.
Patient education
SuPPort
inforMation PackaGe
MyeloMa Hotline: 800-452-cure (2873)
Our free IMF InfoPackTM provides compre-
Toll-free throughout the United States and
hensive information about myeloma, treat-
Canada, the IMF Hotline is staf ed by trained
ment options, disease management, and IMF
information specialists and is in frequent
services. It includes our acclaimed Patient
interaction with members of our Scientific
Handbook.
Advisory Board.
internet acceSS
SuPPort GrouPS
Log on to myeloma.org for 24-hour access to
A worldwide network of more than 100
information about myeloma, the IMF, educa-
myeloma support groups hold regular meet-
tion, and support programs.
ings for members of the myeloma community.
online MyeloMa foruM
The IMF conducts annual summits for leaders
Join the IMF Internet Discussion Group at
of myeloma support group leaders.
www.myeloma.org/listserve.html to share your
reSearcH
thoughts and experiences.
Bank on a cure®
MyeloMa MinuteTM
This DNA bank wil provides genetic data
Subscribe to this free weekly email newslet er
research in new drug development.
for up-to-the-minute information about myeloma.
tHe international StaGinG SySteM (iSS)
iMf Patient & faMily SeMinarSTM
This updated staging system for myeloma
Meet with leading experts in myeloma treat-
enhances physicians' ability to select the most
ment to learn more about recent advances in
appropriate treatment for each patient.
therapy and research.
reSearcH GrantS
MyeloMa MatrixTM
Leading the world in col aborative research
Available on our website, this document is a
and achieving extraordinary results, the IMF
comprehensive guide to drugs in development
Grant Program supports both junior and senior
for myeloma.
researchers working on a broad spectrum of
MyeloMa todayTM newSletter
projects. The IMF has at racted many young
Our quarterly newslet er is available free of
investigators into the field of myeloma; they
charge by subscription.
have remained in the field and are actively
pursuing a cure for this disease.
22
23

---

Glossary
Growth factors: Drugs that stimulate blood stem cel s
both to grow and to be released into the blood-
Alkylating agent: A chemotherapeutic agent such
stream.
as melphalan (Alkeran) or cyclophosphamide
Immune system: The function of a number of related
(Cytoxan). Alkylating refers to the way in which
body organs that protect the body from disease
these agents crosslink the DNA of myeloma cel s and
organisms, other foreign bodies, and cancers.
block cel division.
Immunoglobulin: A protein produced by plasma cel s
Anemia: A decrease in the normal number of red
(a type of white blood cel ) which helps fight infec-
blood cel s, usual y below 10 g/dL with over 13 to
tion. Also known as an antibody.
14 g/dL being normal. Myeloma in the bone mar-
row blocks red cel production, thus causing anemia,
Leukocytosis: Abnormal increase in the number of
the symptoms of which are shortness of breath,
leukocytes (white blood cel s)
weakness, and tiredness.
Leukocytes: White blood cel s
Apheresis: Sometimes cal ed leukapheresis, apheresis
Lytic bone lesions: Holes in the bone.
involves taking blood from a patient or donor. The
M protein (M spike):
white blood cel s, which contain the rare stem cel s,
Antibodies or parts of antibod-
are retained for transplantation and the rest of the
ies found in unusual y large amounts in the blood
blood is returned to the patient or donor.
or urine of myeloma patients. M spike refers to the
sharp pat ern that occurs on protein electrophoresis
Autologous (autograft) stem cell transplantation: Refers
when an M protein is present. Synonymous with
to stem cel s that are col ected from the patient and
monoclonal protein and myeloma protein.
are given back to the same patient after he or she
Monoclonal protein (M protein):
receives high-dose chemotherapy. Most stem cel
An abnormal protein
transplants in myeloma are autologous transplants.
produced by myeloma cel s that accumulates in and
damages bone marrow. A high level of M-protein
Bone marrow: A soft spongy tissue found in most large
indicates that myeloma cel s are present in large
bones that produces red and white blood cel s and
numbers.
platelets.
Multiple myeloma: A cancer arising from the plasma
Chemomobilization: Chemotherapy with growth
cel s in the bone marrow. The plasma cel s in patients
factors.
with multiple myeloma form abnormal antibodies,
Chemotherapy: Treatment with drugs that are used to
possibly damaging the bone, bone marrow, and
kil cancer cel s.
other organs.
Colony-stimulating factor (CSF): Proteins (growth fac-
Orthostatic hypotension: A sudden drop in blood pres-
tors) that stimulate the development and growth of
sure when standing up from a sit ing position.
blood cel s. Neupogen (filgrastim), Neulasta, and
Peripheral blood stem cell (PBSC): Stem cel s col ected
Leukine are colony-stimulating factors that are used
from the blood. These cel s are similar to stem cel s
to mobilize stem cel s from the bone marrow into
found in the bone marrow. The term "peripheral"
the bloodstream prior to apheresis. These may also
means that the cel s come from blood outside of the
be used after the transplant to hasten blood count
marrow.
recovery.
Plasma cell: A type of white blood cel that produces
Granulocyte: A type of white blood cel
antibodies.
24
25

---

Plasmacytoma: A tumor made up of cancerous plasma
Bibliography
cel s.
Platelets: Cel ular fragments critical for blood clot ing
Giralt S, Stadtmauer EA, Harousseau JL, et al.
and sealing of wounds. Platelets also contribute to
International myeloma working group (IMWG)
the immune response. Also known as thrombocytes.
consensus statement and guidelines regarding the
current status of stem cel col ection and high-dose
Red blood cell: A blood cel that carries oxygen from
therapy for multiple myeloma and the role of
the lungs throughout the body.
plerixafor (AMD 3100). Leukemia 2009;23:1904-
Spleen: Organ in the abdomen that filters the blood,
1912.
stores blood cel s, destroys old red blood cel s, and
Keating GM. Plerixafor: a review of its use in
produces white blood cel s.
stem-cel mobilization in patients with lymphoma or
Splenomegaly: Enlarged spleen.
multiple myeloma. Drugs 2011;71:1623-1647.
Stem cell (hematopoietic stem cell): Normal (hematopoi-
Mozobil Patient & Caregiver Education Booklet,
etic, or blood-making) stem cel s give rise to normal
Genzyme Corporation, 2009.
blood components, including red cel s, white cel s,
Mozobil Prescribing Information, Genzyme
and platelets. These stem cel s are normal y located
Corporation, Revised 04/2010.
in the bone marrow and can be harvested for a
transplant.
Mozobil Product Monograph, Genzyme Corporation,
2009.
Subcutaneous: Under the skin.
Tandem transplant: A term used to indicate two
transplants. This may be two autologous trans-
plants or an autologous transplant fol owed by an
al ogeneic (donor) transplant. Tandem transplants
are usual y planned at 3 to 6 month intervals
between transplants.
Thrombocytes: Platelets.
Thrombocytopenia: Abnormal y low numbers of plate-
lets (thrombocytes).
Transplantation (transplant): Stem cel s are used to res-
cue the patient to produce mature and healthy blood
cel s fol owing a very high-dose chemotherapy and/
or radiation treatment. Transplant is not a treatment
but a method of support to make high-dose chemo-
therapy treatment possible.
White blood cell: One of the three major cel types
in the blood. There are several types of white cel s
(i.e., neutrophils, lymphocytes, and monocytes).
26
27

---